CAMKII as a therapeutic target for growth factor–induced retinal and choroidal neovascularization

While anti-VEGF drugs are commonly used to inhibit pathological retinal and choroidal neovascularization, not all patients respond in an optimal manner. Mechanisms underpinning resistance to anti‑VEGF therapy include the upregulation of other proangiogenic factors. Therefore, therapeutic strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashraf, Sadaf, Bell, Samuel, O’Leary, Caitriona, Canning, Paul, Micu, Ileana, Fernandez, Jose A., O’Hare, Michael, Barabas, Peter, McCauley, Hannah, Brazil, Derek P., Stitt, Alan W., McGeown, J. Graham, Curtis, Tim M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482993/
https://www.ncbi.nlm.nih.gov/pubmed/30721154
http://dx.doi.org/10.1172/jci.insight.122442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482993/
https://www.ncbi.nlm.nih.gov/pubmed/30721154
http://dx.doi.org/10.1172/jci.insight.122442

Ejemplares similares